Lumida
/ENTA
⌘K
Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc

ENTA
$12.96USD+2.05%+0.26 today

MARKET CAP

377.5M

P/E (TTM)

FWD P/E

DAY RANGE

$13 – $13

52W RANGE

$7
$17

AI Summary

Stalk
Buy NowHigh

ENTA is in a Stage 2 advancement within a longer-term downtrend. Price has executed a Lockout Rally, reclaiming short- and medium-term EMAs on expanding volume and signaling urgent forced buying. Despite overbought RSI and elevated options interest, the Lockout Rally override supports continued execution readiness. Medium-term bullish permission remains intact, and a Buy Now posture is advised for continuation participation above the mid-June breakout zone.

  • Institutional investors hold 94.99% of shares, underlining strong support
  • Stock price up 64.5% over 12 months despite market headwinds
  • Q3 2026 net loss was $19.5M, versus $18.3M prior year
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$97.1M$86.2M$79.2M$67.6M$65.3M
YoY %-20.7%-11.2%-8.1%-14.6%-3.4%
P / Sales11.8x12.4x2.8x3.2x3.9x
EV / Sales11.6x12.5x4.8x6.4x6.7x
Gross Profit, Adj.$97.1M$86.2M$79.2M$67.6M$65.3M
YoY %-20.7%-11.2%-8.1%-14.6%-3.4%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit11.6x12.5x4.8x6.4x6.7x
EBITDA, Adj.$-106.2M$-120.9M$-134.8M$-119.4M$-80.8M
YoY %-179.6%-13.8%-11.6%+11.5%+32.3%
Margin %-109.4%-140.3%-170.2%-176.5%-123.6%
EV / EBITDA-10.6x-8.9x-2.8x-3.6x-5.4x
EBIT$-109.6M$-123.8M$-137.2M$-121.7M$-85.3M
YoY %-163.1%-13.0%-10.8%+11.3%+29.9%
Margin %-112.9%-143.7%-173.2%-179.9%-130.7%
EV / EBIT-10.3x-8.7x-2.8x-3.5x-5.1x
Net Income$-79.0M$-121.8M$-133.8M$-116.0M$-81.9M
YoY %-118.4%-54.1%-9.9%+13.3%+29.4%
Net Margin-81.4%-141.3%-169.0%-171.6%-125.4%
EPS (GAAP)-$3.92-$5.91-$6.38-$5.48-$3.84
YoY %-116.6%-50.8%-8.0%+14.1%+29.9%